EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proteomic Profiles Associated With Postsurgical Progression in Nonfunctioning Pituitary Adenomas

Tobias Hallén iD, Gudmundur Johannsson iD, Annika Thorsell, Daniel S Olsson iD, Charlotte Örndal, Angelica Engvall, Frida Jacobson, Anna Widgren, Jonas Bergquist iD, Thomas Skoglund iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad767 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Tobias Hallén und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Sahlgrenska University Hospital, 412 65 Gothenburg, Sweden. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Disease Progression, Proteomics, Adenoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish state, Swedish government, County Councils.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

There is a lack of reliable biomarkers capable of predicting postoperative tumor progression of nonfunctioning pituitary adenomas (NFPAs).

Objective

To discover proteomic profiles associated with postoperative tumor progression in patients with NFPAs. This was a case-controlled exploratory study at a tertiary university hospital. Tissue samples were obtained from 46 patients with residual tumor following surgery for NFPAs of gonadotroph lineage. Two patient groups were compared: patients requiring reintervention due to residual tumor progression (cases; reintervention group, n = 29) and patients with a residual tumor showing no progression for a minimum of 5 years (controls; radiologically stable group, n = 17). Differentially expressed proteins (DEPs) between patient groups were measured.

Results

Global quantitative proteomic analysis identified 4074 proteins, of which 550 were differentially expressed between the 2 groups (fold change >80%, false discovery rate–adjusted P ≤ .05). Principal component analysis showed good separation between the 2 groups. Functional enrichment analysis of the DEPs indicated processes involving translation, ROBO-receptor signaling, energy metabolism, mRNA metabolism, and RNA splicing. Several upregulated proteins in the reintervention group, including SNRPD1, SRSF10, SWAP-70, and PSMB1, are associated with tumor progression in other cancer types.

Conclusion

This is the first exploratory study analyzing proteomic profiles as markers of postoperative tumor progression in NFPAs. The findings clearly showed different profiles between tumors with indolent postoperative behavior and those with postoperative tumor progression. Both enriched pathways involving DEPs and specific upregulated proteins have previously been associated with tumor aggressiveness. These results suggest the value of proteomic profiling for predicting tumor progression in patients with NFPAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary NeoplasmsDisease ProgressionProteomicsAdenomaHumansFemaleMaleMiddle AgedAdultCase-Control StudiesBiomarkers, TumorNeoplasm, ResidualAgedProteome

Stichwörter der Autor:innen

nonfunctioning pituitary adenomaquantitative proteomicsreinterventiontumor progression

Substanzen

Biomarkers, TumorProteome

Autor:innen und Institutionen

  • Department of Neurosurgery, Sahlgrenska University Hospital, 412 65 Gothenburg, Sweden.
  • Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden.
  • Department of Endocrinology, Sahlgrenska University Hospital, 413 46 Gothenburg, Sweden.
  • Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden.
  • Proteomics Core Facility at Sahlgrenska Academy, Gothenburg University, 413 90 Gothenburg, Sweden.
  • Late-stage Clinical Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 431 83 Gothenburg, Sweden.

ORCID-Profile: Tobias Hallén, Gudmundur Johannsson, Daniel S Olsson, Jonas Bergquist, Thomas Skoglund

Förderung

  • Swedish state
  • Swedish government
  • County Councils
  • ALF-agreement
  • Swedish Cancer Society
  • Health & Medical Care Committee
  • Västra Götaland Region, Sweden
  • The Swedish Society of Medicine

Zitieren

APA

Hallén, T., Johannsson, G., Thorsell, A., Olsson, D. S., Örndal, C., Engvall, A., Jacobson, F., Widgren, A., Bergquist, J., & Skoglund, T. (2024). Proteomic Profiles Associated With Postsurgical Progression in Nonfunctioning Pituitary Adenomas. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad767

Vancouver

Hallén T, Johannsson G, Thorsell A, Olsson DS, Örndal C, Engvall A, et al. Proteomic Profiles Associated With Postsurgical Progression in Nonfunctioning Pituitary Adenomas. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad767

BibTeX
@article{Halln2024,
  author = {Hallén, Tobias and Johannsson, Gudmundur and Thorsell, Annika and Olsson, Daniel S and Örndal, Charlotte and Engvall, Angelica and Jacobson, Frida and Widgren, Anna and Bergquist, Jonas and Skoglund, Thomas},
  title = {Proteomic Profiles Associated With Postsurgical Progression in Nonfunctioning Pituitary Adenomas},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad767}
}
Kostenlos starten →